Researchers Published Review on Cancer-Linked RNAs
A 2026 review in Genes & Diseases explored how lncRNAs influence tumor survival and potential therapeutic interventions.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you believe current genetic research will lead to better cancer treatment options for patients?
In 2026, researchers published a review in Genes & Diseases identifying long non-coding RNAs (lncRNAs) as critical regulators of gene expression in various cancers. This study examined how these molecules contribute to treatment failure and tumor resistance.
Why it matters
Tumors often develop complex mechanisms to survive traditional therapies, contributing to high rates of treatment failure. Understanding these RNA regulators provides a foundation for developing more effective, targeted cancer interventions.
The study, published in Volume 13, Issue 6 (Article 101990), analyzes lncRNAs like MALAT1, HOTAIR, PVT1, NEAT1, and UCA1. These molecules were found to influence processes such as apoptosis, autophagy, DNA repair, and drug efflux across seven different cancer types.
The players
Genes & Diseases
This is a peer-reviewed academic journal that publishes research regarding the molecular and cellular mechanisms of various human diseases.
The details
The review analyzed how lncRNAs regulate gene expression, microRNAs, and proteins in breast, lung, gastric, liver, cervical, colorectal, and nasopharyngeal cancers. Researchers suggested that future therapies could utilize antisense oligonucleotides, RNA interference, and CRISPR/Cas9 gene editing to target these survival mechanisms.
Timeline
2026: The review was published in Volume 13 of the journal Genes & Diseases.
The Big Picture
This study advances the integration of the CRISPR/Cas9 gene editing framework into oncology research to address complex tumor resistance. The findings extend the application of these genetic tools by identifying specific RNA targets that could be modulated to improve patient outcomes.
While this research offers insight into future therapeutic targets, it does not currently change available treatment options or clinical protocols. Patients should continue to consult with their oncologists regarding established care plans while long-term safety and delivery methods for RNA therapies are investigated.
The takeaway
This review highlights the critical role of lncRNAs in how cancer cells survive medical interventions. Future research into delivery methods like lipid nanoparticles will be essential to translate these genetic findings into viable patient treatments.
Further reading
For more information on current developments, visit the Cancer section.
More information
View the full journal article research publication for technical details on the study.
Live Poll
Do you believe current genetic research will lead to better cancer treatment options for patients?
